Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline
Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.
You may also be interested in...
Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
As Takeda prepares to report its first full quarter post-Shire next week, eyes will be on further strategic divestments and trends that could lead to a raising of guidance in Q2.